Industry Leaders Discuss the Impact of FDA's Diversity Action Plan
July 3rd 2024Pamela Tenaerts, MD, MBA, chief scientific officer, Medable; Luke Gelinas, PhD, senior chair director, Advarra; and Pam Diamond, MD, chief medical officer & co-founder, Curavit highlight the potential impact FDA's Diversity Action Plan guidance will have on industry.
Industry Leaders React to FDA's Newly Announced Diversity Action Plan Guidance
July 2nd 2024Pamela Tenaerts, MD, MBA, chief scientific officer, Medable; Luke Gelinas, PhD, senior chair director, Advarra; and Pam Diamond, MD, chief medical officer & co-founder, Curavit share their initial thoughts on the announcement of FDA's Diversity Action Plan guidance.
DIA 2024: Ginny Beakes-Read of Johnson & Johnson Discusses Regulatory Challenges
June 21st 2024In an interview with ACT editor Andy Studna at DIA 2024, Beakes-Read, head, global regulatory policy and intelligence, Johnson & Johnson Innovative Medicine highlights the integration of technological advancements into drug development and benefits patients are seeing from FDA's Accelerated Approval Program.
DIA 2024: Allison Cuff Shimooka of TransCelerate Biopharma Discusses Innovation in Clinical Research
June 20th 2024In an interview with ACT editor Andy Studna at DIA 2024, Cuff Shimooka, chief operating officer of TransCelerate Biopharma touches on how collaboration will be key to innovation in clinical research moving forward.